CN-105

DRUG4 trials

Sponsors

AegisCN LLC, Miles Berger, MD PhD, Beijing Tiantan Hospital

Conditions

Intracerebral HemorrhageIntracerebral Hemorrhage (ICH)Postoperative Cognitive DysfunctionPostoperative Delirium

Phase 1

Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage

CompletedNCT02670824

AegisCN LLCIntracerebral Hemorrhage (ICH)

Start: 2015-12-31End: 2016-08-31Updated: 2016-08-18

Phase 2

A Proof of Concept Study to Evaluate CN-105 in ICH Patients

CompletedNCT03168581

AegisCN LLCIntracerebral Hemorrhage

Start: 2017-08-28End: 2020-01-25Updated: 2020-03-11

Modulating ApoE Signalling to Reduce Brain Inflammation, deLirium and postopErative Cognitive Dysfunction

CompletedNCT03802396

Miles Berger, MD PhDPostoperative Cognitive Dysfunction, Postoperative Delirium

Start: 2018-07-15End: 2022-12-28Updated: 2024-10-16

A Study Evaluating the Safety and Efficacy of Neuroprotective Peptide CN-105 Peptide in Patients With Acute Supratentorial Intracerebral Hemorrhage

RecruitingNCT06255977

Beijing Tiantan HospitalIntracerebral Hemorrhage

Start: 2022-08-24End: 2024-08-31Target: 240Updated: 2024-02-13

Related Papers

Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients

JAMA Network Open2026-04-03

Tolerability and Pharmacokinetics of Single Escalating and Repeated Doses of CN-105 in Healthy Participants.

2022-05-113 citations